Sarilumab and Polymyalgia Rheumatica

CEimpact Podcast

Polymyalgia rheumatica is a common rheumatic disorder. Steroids are the mainstay of therapy despite significant adverse reactions. Join host, Geoff Wall, as he evaluates a new treatment for PMR.
The GameChanger
Sarilumab is now FDA-approved for relapsing polymyalgia rheumatica. Sarilumab can be an alternative to long-term steroid therapy or methotrexate.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, Akinlade B, Wong W, Bhore R, Lin Y, Buttgereit F, Devauchelle-Pensec V, Rubbert-Roth A, Yancopoulos GD, Marrache F, Patel N, Dasgupta B; SAPHYR Investigators. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med. 2023 Oct 5;389(14):1263-1272. doi: 10.1056/NEJMoa2303452. PMID: 37792612.
https://www.nejm.org/doi/full/10.1056/NEJMoa2303452

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the diagnosis and treatment of polymyalgia rheumatica
2. Assess the SAPHYR study and the role of sarilumab for treatment of polymyalgia rheumatica
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-352-H01-P
Initial release date: 11/6/2023
Expiration date: 11/6/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Kapitler

1. Sarilumab and Polymyalgia Rheumatica (00:00:00)

2. New Medication for Polymyositromatica (PMR) Treatment (00:00:07)

3. Interleukin-6 Blockers in PMR Treatment (00:10:39)

4. Severellumab for PMR (00:18:55)